Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres

El-Gibaly, I.

doi:10.1016/s0378-5173(02)00396-4

Cited by 123 publications

(69 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…DSC thermograms of chitosan (pure), TA (pure), and TA-loaded chitosan microspheres are shown in Figures 2a-c, respectively. Under the experimental conditions no characteristic endothermy was obtained for pure chitosan, as reported earlier (He et al, 1999;El-Gibaly, 2002). However, thermograms of pure TA Figure 2b) revealed endothermic peaks at 278°C, which clearly resembles the reported value of the melting point of triamcinolone.…”

Section: Resultssupporting

confidence: 82%

Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: Prolonged release approach for the treatment of rheumatoid arthritis

Dhanaraju¹,

Elizabeth

Gunasekaran³

2010

Drug Delivery

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 82%

Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: Prolonged release approach for the treatment of rheumatoid arthritis

Dhanaraju¹,

Elizabeth

Gunasekaran³

2010

Drug Delivery

View full text Add to dashboard Cite

“…The obtained beads were studied for buoyancy 12 and floating time using USP Apparatus II (paddle type). One hundred beads of each batch were placed in 900 ml of 0.1 N HCl (pH 1.2) containing 0.02% w/v Tween 80 and agitated at 50 rpm, temperature was maintained at 37ºC.…”

Section: Encapsulation Efficiency = (Aq/tq) X 100mentioning

confidence: 99%

Formulation and Evaluation of Floating Alginate Beads of Diclofenac Sodium

Rasel

Hasan

2012

Dhaka Univ. J. Pharm. Sci

View full text Add to dashboard Cite

ABSTRACT:The objective of this present investigation is to develop gastroretentive sustained release alginate beads of Diclofenac sodium by the ionotropic gelation method. The floating beads were prepared by dispersing Diclofenac sodium together with CaCO 3 (as gas forming agent) into a solution of sodium alginate. The resulting solution was then extruded through a 22 gauge syringe needle into 100 ml cross-linking solution containing calcium chloride (1% w/v) plus acetic acid (10% v/v). Prepared beads were evaluated for their encapsulation efficiency, buoyancy test, FT-IR spectroscopy, scanning electron microscopy (SEM) and release behaviour. In vivo floating behaviour was studied by sonography. The drug entrapment efficiency was increased with the increment of polymer ratio. All of the formulations (F1 to F5) floated immediately or with a very short lag time and remained floating upto 24 hours. Rough and porous surface was observed in case of surface SEM and many large hollow pores or multiple small hollow pockets were observed in case of cross-sectional SEM of beads. In vivo floating behaviour of the beads was confirmed by ultrasonographic examination of a healthy male volunteer after ingestion of capsule containing floating beads. In vitro dissolution studies were performed for eleven hours into 900 ml 0.1N HCl (pH 1.2) using USP Apparatus II (paddle type) maintained at a temperature of 37ºC and stirred at a speed of 50 rpm. The dissolution study revealed that, after eleven hours the percent of drug release for five formulations were 76.7% (F1), 73.5 % (F2), 72.2 % (F3), 70.56% (F4), and 69.1 % (F5) and all of the formulations followed zero order and Higuchi model.

show abstract

“…The differential scanning calorimetry thermogram of chitosan showed an endothermic peak at 180°C and an exothermic peak at 370°C which are ascribed, respectively, to hydrogenbonding dissociation and degradation of this polymer. 32,33 The differential scanning calorimetry plot obtained for doxorubicin revealed an endothermic melting peak at 200°C with endothermic peaks of degradation appearing at higher temperatures. Conjugation of doxorubicin to chitosan led to a shift in hydrogen-bonding dissociation and degradation peaks of chitosan, while no trace of the doxorubicin peaks was observed in the differential scanning calorimetry thermogram of CS-DOX.…”

Section: Discussionmentioning

confidence: 99%

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

Sakhtianchi¹,

Atyabi²,

Yousef³

et al. 2011

IJN

View full text Add to dashboard Cite

Background Targeting drugs to their sites of action to overcome the systemic side effects associated with most antineoplastic agents is still a major challenge in pharmaceutical research. In this study, the monoclonal antibody, trastuzumab, was used as a targeting agent in nanoparticles carrying the antitumor drug, doxorubicin, specifically to its site of action. Methods Chitosan-doxorubicin conjugation was carried out using succinic anhydride as a crosslinker. Trastuzumab was conjugated to self-assembled chitosan-doxorubin conjugate (CS-DOX) nanoparticles (particle size, 200 nm) via thiolation of lysine residues and subsequent linking of the resulted thiols to chitosan. Conjugation was confirmed by gel permeation chromatography, differential scanning calorimetry, Fourier transform infrared spectroscopy, and 1 H nuclear magnetic resonance spectroscopy studies. Dynamic light scattering, transmission electron microscopy, and zeta potential determination were used to characterize the nanoparticles. Results CS-DOX conjugated nanoparticles had a spherical shape and smooth surface with a narrow size distribution and core-shell structure. Increasing the ratio of doxorubicin to chitosan in the conjugation reaction gave rise to a higher doxorubicin content but lower conjugation efficiency. Trastuzumab-decorated nanoparticles (CS-DOX-mAb) contained 47 μg/mg doxorubicin and 33.5 μg/mg trastuzumab. Binding of trastuzumab to the nanoparticles was further probed thermodynamically by isothermal titration calorimetry. Fluorescence microscopy demonstrated enhanced and selective uptake of CS-DOX-mAb by Her2 + cancer cells compared with nontargeted CS-DOX nanoparticles and free drug. Conclusion Antibody-conjugated nanoparticles were shown to discriminate between Her2 + and Her2 − cells, and thus have the potential to be used in active targeted drug delivery, with reduction of drug side effects in Her2 + breast and ovarian cancers.

show abstract

Development and in vitro evaluation of novel floating chitosan microcapsules for oral use: comparison with non-floating chitosan microspheres

Cited by 123 publications

References 26 publications

Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: Prolonged release approach for the treatment of rheumatoid arthritis

Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: Prolonged release approach for the treatment of rheumatoid arthritis

Formulation and Evaluation of Floating Alginate Beads of Diclofenac Sodium

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

Contact Info

Product

Resources

About